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SUMMARY 
The aim of the present study was to analyse pharmacodynamic effects of a dexmedetomidine 
constant rate infusion (CRI) during general anaesthesia. This experimental study included six 
isoflurane anaesthetised horses, which during anaesthesia received a 1.75 µg·kg-1·hour-1 
dexmedetomidine CRI. Physiological parameters were measured and blood samples (both 
samples for blood gas analysis and dexmedetomidine plasma concentration analysis) were 
collected continuously during the entire anaesthesia and for 60 minutes after the CRI was 
disconnected.  
All horses quickly reached a significant dexmedetomidine plasma concentration after the 
dexmedetomidine CRI was commenced. Mean dexmedetomidine concentration in plasma 
stayed above 0.15 ng·mL-1 during the entire anaesthesia, including 60 minutes after the 
dexmedetomidine CRI was disconnected. A previous study reported a dexmedetomidine 
plasma concentration of 0.15 ng·mL-1 to correspond to the nociceptive threshold in conscious 
horses.  
Heart rate decreased significantly during the first hour after the dexmedetomidine CRI was 
started and mean arterial blood pressure was significantly increased during the first 15 
minutes. Cardiac index decreased in five of six horses after dexmedetomidine was 
administrated but the mean value was not significantly different compared to baseline. The 
overall cardiovascular changes were expected and within clinically acceptable levels. The 
termination of dexmedetomidine CRI during ongoing anaesthesia caused significant 
tachycardia for at least 30 minutes in all horses, a finding not described in previous studies. 
There was no significant reduction in end-tidal isoflurane concentration during the course of 
anaesthesia. 
Treatment of expected complications during inhalation anaesthesia in horses, e.g. hypotension 
and hypoxemia, were successfully treated with dobutamine and pulsed inhaled nitrogen 
monoxide.  
In summary, the dexmedetomidine CRI during inhalation anaesthesia in horses seems to be a 
promising clinical method to improve analgesia and sedation during anaesthesia and recovery. 
The unexpected circulatory change in the form of tachycardia after the CRI needs to be 
investigated further.  
  
 
SAMMANFATTNING 
Syftet med studien var att analysera farmakadynamiska effekter vid CRI (constant rate 
infusion) av dexmedetomidin under inhalationsanaestesi. Denna experimentella studie 
inkluderade sex hästar sövda med isofluran, som under anestestesin erhöll ett CRI med 
dexmedetomidin på 1.75 µg·kg-1·h-1. Fysiologiska parametrar mättes och blodprover (både 
prover för blodgasanalys och analys av dexmedetomidinkoncentration i plasma) samlades in 
kontinuerligt under hela anestesin samt 60 minuter efter att infusionen med dexmedetomidin 
stängts av.  
Samtliga hästar nådde snabbt en signifikant koncentration av dexmedetomidin i plasma efter 
att infusionen med dexmedetomidin påbörjats. Medelkoncentrationen dexmedetomidin i 
plasma var över 0.15 ng·mL-1 under hela anestesin, inklusive 60 minuter efter att infusionen 
med dexmedetomidin stängts av. En tidigare studie har visat att 0.15 ng·mL-1 motsvarar den 
nociceptiva tröskeln för dexmedetomidin hos vaken häst.  
Efter att dexmedetomidin-infusionen startats sjönk hjärtfrekvensen signifikant under den 
första timmen medan medelartärtryck ökade signifikant under de första 15 minuterna. 
Cardiac index minskade hos fem av sex hästar under dexmedetomidininfusionen men 
förändringen i medelvärde var inte signifikant. Överlag var de kardiovaskulära förändringarna 
förväntade och de höll sig inom en klinisk acceptabel nivå. Avslutningen av 
dexmedetomidininfusionen under pågående anestesi orsakade signifikant takykardi under 
minst 30 minuter hos samtliga hästar, ett fynd som inte finns beskrivet i tidigare studier. 
Ingen signifikant reducering av den end-tidal isoflurankoncentration kunde genomföras med 
bibehållet narkosdjup i denna studie. 
Behandling av förväntade komplikationer under inhalationsanestesi på häst, t.ex. hypotension 
och hypoxemi, kunde framgångsrikt behandlas med dobutamin respektive pulsat inhalerat 
kvävemonoxid. 
Sammanfattningsvis kan CRI med dexmedetomidin vara en tänkbar klinisk metod för att 
förbättra analgesi och sedering under både anestesi- och uppvakningsperioden. De oväntade 
cirkulatoriska förändringarna i form av takykardi när behandlingen avbröts behöver studeras 
vidare.  
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ABBREVIATIONS 
ASA  American Society of Anaesthesiologists 
CI  Cardiac index (mL·kg-1·min-1) 
CO  Cardiac output (L·min-1) 
CRI  Continuous rate infusion 
CVP  Central venous pressure (mmHg) 
DAP  Diastolic arterial pressure (mmHg) 
EtCO2  End-tidal carbon dioxide concentration (%) 
EtO2  End-tidal oxygen concentration (%) 
EtISO  End-tidal isoflurane concentration (%) 
FiO2  Fraction inspired oxygen (%) 
HR  Heart rate (beats/min) 
IPPV  Intermittent positive pressure ventilation 
MAC  Minimal alveolar concentration 
MAP  Mean arterial pressure (mmHg) 
NO  Nitric oxide 
RR  Respiratory rate (breaths·min-1) 
SaO2  Oxygen saturation in blood (%) 
SAP  Systolic arterial pressure (mmHg) 
SV  Stroke volume (L·beat-1) 
SVR  Systemic vascular resistance (mmHg·min·L-1) 
SVRI  Systemic vascular resistance index (mmHg·min·L-1·kg-1) 
PaO2  Partial pressure of oxygen in arterial blood (kPa) 
PAPD  Pulmonary artery pressure diastolic (mmHg) 
PAPM  Pulmonary artery pressure mean (mmHg) 
PAPS  Pulmonary artery pressure systolic (mmHg) 
PA wedge  Pulmonary arterial wedge pressure (mmHg) 
PEEP  Peak end expiratory pressure (cmH2O) 
PiNO  Pulse-delivered inhaled nitric oxide  
PIP  Peak inspiratory pressure (cmH2O) 
TV  Tidal volume (L) 
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INTRODUCTION 
General anaesthesia in horses entails a higher risk for complications compared to anaesthesia 
in small animals or humans (Johnston et al., 2002). Most of the mortalities are related to the 
anaesthesia (Gozalo-Marcilla et al., 2010) and a total volatile anaesthesia is associated with a 
higher mortality risk than a total intravenous anaesthesia (Valverde, 2013). Different balanced 
anaesthetic protocols are often used in order to minimize the amount of inhalation 
anaesthetics, increase the anaesthetic depth and provide analgesia. By combining multiple 
anaesthetic and analgesic drugs the goal is to make them act synergistically considering the 
desired analgesic effects and minimize the side effects (Gozalo-Marcilla et al., 2012). Several 
studies have shown that adding a CRI of an α2-agonist reduces the minimal alveolar 
concentration (MAC) of the inhalation gas significantly, most likely due to its sedative and 
analgesic effects (Gozalo-Marcilla et al., 2015).  
Until 2005 there had not been any reported studies in the subject of administrating 
dexmedetomidine to horses. Since then several studies have been performed and 
dexmedetomidine is now starting to be a popular drug used as an intravenous infusion, both in 
standing procedures and partial/total intravenous anaesthesia (PIVA/TIVA) (Gozalo-Marcilla 
et al., 2017). The minimal cardiopulmonary side effects reported with dexmedetomidine 
favour its use over other α2-agonists (Bettschart-Wolfensberger et al., 2005). 
Dexmedetomidine given as a CRI during anaesthesia is showing a lot of promise and can 
come to play an important role in equine anaesthesia in the future. However, more studies are 
needed to further investigate the pharmacodynamic and pharmacokinetic effects of 
dexmedetomidine during anaesthesia (Rezende et al., 2015).  
In the present study a dexmedetomidine CRI with a concentration of 1.75 µg·kg-1·hour-1 was 
used. A dexmedetomidine CRI during anaesthesia has been shown to reduce the needed 
concentration of inhalation anaesthetics (Gozalo-Marcilla et al., 2013a; Gozalo-Marcilla et 
al., 2013b; Gozalo-Marcilla et al., 2014; Risberg et al., 2016). A previous study has 
determined the nociceptive threshold to correspond to a dexmedetomidine plasma 
concentration of 0.15 ng·mL-1, in conscious horses (Risberg et al., 2014), and that threshold 
was used in the present study. In the present study pulsed inhaled nitric oxide (PiNO) was 
also added during the anaesthesia, in order to treat hypoxemia, as described in previous 
studies (Grubb et al., 2008; Grubb et al., 2012b; Nyman et al., 2012; Grubb et al., 2013; 
Wiklund, 2014). 
This was the first study to analyse physiological effects during the elimination phase of 
dexmedetomidine (after the CRI was disconnected) in anaesthetised horses. Nor has any 
previous study analysed the pharmacodynamic and pharmacokinetic effects of a 
dexmedetomidine CRI in anaesthetised horses without a prior loading dose (or premedication) 
of dexmedetomidine. 
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Aims and hypothesis 
In this experimental study the physiological effects of an intravenous infusion of dexmede-
tomidine with the concentration 1.75 µg·kg-1·hour-1 was investigated in six isoflurane 
anaesthetised horses. The aim was to study i) if the dexmedetomidine CRI resulted in a 
plasma concentration above the nociceptive threshold (0.15 ng·mL-1); ii) the physiological 
effects during and after a dexmedetomidine CRI; iii) if the isoflurane concentration could be 
reduced during the CRI; iv) the effects on arterial oxygenation with PiNO during a 
dexmedetomidine CRI.  
Our hypothesis was that a dexmedetomidine CRI would affect the circulation by a decrease in 
heart rate and cardiac index meanwhile arterial blood pressure increased. We also expected to 
be able to reduce the end-tidal isoflurane concentration by adding a dexmedetomidine CRI to 
the anaesthesia. 
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LITERATURE REVIEW 
Anaesthesia in horses 
Equine surgery is today a very important part in treating injuries and diseases in our horses. 
Surgeries are performed both under general anaesthesia and during standing procedures on 
conscious horses (HästSverige, 2016). It is well known that anaesthesia in horses is associated 
with a higher mortality and morbidity compared to anaesthesia in small animals and humans. 
The cardiovascular depression (hypotension, reduced blood flow and hypoventilation) is more 
explicit in horses than in dogs and cats (Lee, 2006). Studies have shown a mortality rate of 
1% in healthy horses undergoing elective surgery (compared to a mortality rate of 0.01-
0.001% in humans). In emergency cases and in horses with systemic disease the mortality rate 
is much higher (Dugdale & Taylor, 2016). Many of the mortalities are related to the 
cardiovascular depression seen with inhalation anaesthesia (Gozalo-Marcilla et al., 2010). 
Balanced anaesthesia means combining several anaesthetics/analgesics/sedatives in order to 
summate the advantage effects and avoid disadvantage effects. The horse is being sedated, the 
pain is minimized and the dose-dependent side effects seen with total volatile anaesthetics are 
reduced (Bettschart-Wolfensberger et al., 2007). Many studies have been performed in order 
to produce a safer and more beneficial anaesthesia (Johnston et al., 2002). Different 
intravenous drugs have long been used as supplements to inhalational anaesthesia (Gozalo-
Marcilla et al., 2015). 
Isoflurane is a well-used inhalation anaesthetic in equine anaesthesia. It induces a peripheral 
vasodilation and hypotension. The cardiovascular depression is dose-dependent, as with other 
inhalation anaesthetics. Since isoflurane depresses the respiratory function, isoflurane is 
usually combined with intermittent positive pressure ventilation (IPPV), a controlled 
ventilation where lung inflation is produced by a positive pressure (Lee, 2006), improving 
alveolar ventilation (Kalchofner et al., 2009).  
Maintenance of a good blood flow is crucial in order to achieve sufficient oxygenation and 
prevent hypoxemia (Gozalo-Marcilla et al., 2010). Under clinical circumstances the horse 
often receives dobutamine during anaesthesia in order to prevent hypotension and improve 
central and muscular blood flow. Dobutamine is a synthetic catecholamine and is an inotropic 
drug. It stimulates β1-adrenergic receptors and increases cardiac output by an increase in 
myocardial contractility (Ohta et al., 2013).  
The position of the horse during anaesthesia will likely induce cardiovascular and respiratory 
changes (Doherty et al., 2006). When placed in dorsal recumbency the expansion of the lungs 
is reduced due to compression of the abdominal contents on the diaphragm (Lee, 2006). 
Horses easily develop hypoxemia (defined as PaO2 of <8.0 kPa) during anaesthesia when 
blood is shunted through the lungs without gas exchange (Auckburally & Nyman, 2017). This 
occurs because most of the blood is distributed to the caudodorsal parts of the lungs, even 
though those parts become atelectatic when the horse is placed in dorsal recumbency. The 
well-ventilated cranioventral parts of the lungs come in contact with only a small proportion 
of the circulating blood (Wiklund 2014).  
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One way to redistribute the blood to ventilated lung regions is by administrating nitric oxide 
(NO) during anaesthesia. Inhaling NO causes a selective, local pulmonary vasodilation 
(Wiklund, 2014) in contrast to administrating NO systemically leading to a generalised 
vasodilation and through that causing a peripheral hypotension (Auckburally & Nyman, 
2017). The shunt fraction is reduced which improves the gas exchange and the arterial 
oxygenation. This effect is seen both in spontaneously breathing horses and when they are 
mechanically ventilated. The improved shunt fraction is only seen when the NO is pulsed 
(PiNO) in the beginning of the breaths, not during the second half of the breaths (Auckburally 
& Nyman, 2017). In higher doses NO can be toxic and exhaled NO can interfere with the 
soda lime in the breathing circuit (Wiklund, 2014). 
Dexmedetomidine 
Dexmedetomidine is the most selective α2-agonist with high affinity (1620:1) for the α2-
receptor. For over 15 years, dexmedetomidine has been used clinically in dogs and cats; 
however it is not indicated for use in horses yet (Gozalo-Marcilla et al., 2017). 
Dexmedetomidine is the active enantiomer of medetomidine (Savola & Virtanen, 1991). 
Medetomidine consists of equal parts of dexmedetomidine and levomedetomidine. Dexmede-
tomidine is responsible for the sedative and analgesic effects, while levomedetomidine 
potentiate bradycardia and reduce the sedative and analgesic effect (Kuusela et al., 2001). 
Dexmedetomidine, like other α2-agonists, decreases the concentration of epinephrine and 
norepinephrine in plasma. The lower concentration of catecholamines affects many 
physiological functions and causes sedation (Grimsrud et al., 2015). Alpha-2 agonists depress 
cardiopulmonary function, induce bradycardia and decrease cardiac output (CO). The 
magnitude of the side effects depends on type of α2-agonist, its dose and route of 
administration (Hopster et al., 2014). Alpha-2 agonists increase vascular resistance by 
receptor activation, followed by a reflex bradycardia. The bradycardia is additionally induced 
via central mechanisms (Maze & Tranquilli, 1991). 
Dexmedetomidine causes the same side effects as other α2-agonists but of very short duration 
because of a rapid redistribution, large volume of distribution, and short half-life. This 
indicates that plasma concentration of dexmedetomidine rapidly can be adjusted during 
anaesthesia (Bettschart-Wolfensberger et al., 2005). 
There are three subtypes of the receptor; α2A-receptors mediate sedation, analgesia (both 
visceral and somatic), bradycardia and hypotension; α2B-receptors mediate vascular resistance 
and bradycardia; α2C-receptors mediate hypothermia. Alpha-2 receptors are located 
extrasynaptically in vascular endothelium, in platelets and pre- and postsynaptically 
throughout the body (Tranquilli et al., 2007).  
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Previous studies 
Dexmedetomidine as an intravenous bolus dose in standing horses 
Administration of dexmedetomidine to horses was first studied in a report published by 
Bettschart et al. (2005). Eight young ponies (group A) and six mature ponies (group B) both 
received a bolus dose of 3.5 µg·kg-1. In group A pharmacodynamic parameters and blood 
gases were analysed continuously for 60 minutes after administration. In both groups kinetic 
blood samples were collected continuously for 240 minutes after administration. Within 60-90 
minutes the plasma concentration of dexmedetomidine had drop below limit of detection 
(0.05 ng·mL-1) in both groups. Half-life was longer in the older ponies (29 minutes) compared 
to the younger ponies (20 minutes). The horses in group A showed a significant decrease in 
cardiac index (CI), a significant increase in mean arterial blood pressure (MAP) and systemic 
vascular resistance index (SVRI), however the changes were only significant the first five to 
ten minutes after the bolus dose was administrated. No significant reduction in heart rate (HR) 
was observed.  
Rezende et al. (2015) analysed pharmacodynamic and pharmacokinetic effects of dexmede-
tomidine in eight standing horses receiving a bolus dose of 5 µg·kg-1. Blood samples were 
collected for pharmacokinetic calculations. Physiological parameters were analysed before 
and continuously for six hours after administration. Half-life was eight minutes and within 30-
60 minutes the concentration of dexmedetomidine in plasma was below 0.1 ng·mL-1. Heart 
rate decreased significantly for the first ten minutes after administration.  
Dexmedetomidine as a CRI in standing horses 
Several studies have been performed regarding standing procedures in conscious horses 
receiving dexmedetomidine as a CRI. In a report by Risberg et al. (2014) ten horses were 
sedated with a dexmedetomidine CRI in three different concentrations (first 2 µg·kg-1·hour-1, 
then 4 µg·kg-1·hour-1 and last 6 µg·kg-1·hour-1). A 0.96 µg·kg-1 bolus dose preceded each 
CRI. The horses were electrically stimulated in order to determine tolerance and nociceptive 
threshold by analysing behaviour and electromyography. A median plasma concentration of 
0.15 ng·mL-1 dexmedetomidine was considered to provide nociceptive effects in all analysed 
parameters in the study. In all three CRI concentrations antinociceptive effects were seen, 
although the concentration of dexmedetomidine in plasma during the 2 µg·kg-1·hour-1 CRI 
was to low too be measured. There was a big individual variation in plasma concentration 
between the horses (Risberg et al., 2014).  
A study by Ranheim et al. (2015) showed a significant individual difference in plasma 
concentration of dexmedetomidine during a 150 minutes long 8 µg·kg-1·hour-1 CRI in seven 
horses. Kinetic blood samples were taken continuously during the CRI and for approximately 
one hour after the CRI ended. Mean plasma elimination half-life was 20.9 minutes. The 
sedation effect covaried with the plasma concentration level. No pharmacodynamic effects 
were observed in this study.  
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Dexmedetomidine as a CRI during anaesthesia 
Several studies have been performed where different α2-agonists (xylazine, romifidine, 
detomidine and medetomidine) significantly have reduced MAC of isoflurane, sevoflurane or 
halotane (Gozalo-Marcilla et al., 2013a). Both experimental and clinical studies have shown 
that a medetomidine CRI provides good recovery and analgesia during surgery and 
cardiopulmonary function remained stable. In humans and dogs studies have shown a 
significant reduction of MAC of isoflurane when given a dexmedetomidine CRI (Gozalo-
Marcilla et al., 2010). 
The first documented study to administrate dexmedetomidine as a CRI during inhalation 
anaesthesia to horses, observed the cardiopulmonary effects in six ponies receiving two 
different dose rates of dexmedetomidine. Three ponies were administrated 1 µg·kg-1·hour-1 
for 30 minutes and then 1.75 µg·kg-1·hour-1 for 30 minutes (after a washout period of 30 
minutes between the two infusions). The other three ponies received the infusions in the 
opposite order. A 3.5 µg·kg-1 bolus dose of dexmedetomidine was administered as 
premedication in both groups before the first CRI. This experimental study showed that HR, 
CI and oxygen delivery decreased significantly while SVRI, SAP and right arterial pressure 
increased significantly. These effects were statistically significant but the cardiovascular 
function remained within a clinically acceptable level. No significant differences in the results 
were seen between the two different doses (Gozalo-Marcilla et al., 2010). 
Gozalo-Marcilla et al. (2012) did a rather comprehensive clinical study (blinded, placebo-
controlled and randomized) including 40 horses undergoing elective surgery (ASA I-II). The 
horses were anaesthetised with isoflurane and premedicated with a 3.5 µg·kg-1 bolus dose of 
dexmedetomidine. One group of horses (group D) received a CRI of 1.75 µg·kg-1·hour-1 and 
the other group of horses (group S) received a saline CRI and functioned as a control group. 
In this study there was no significant difference between the two groups regarding the 
concentration of inhaled isoflurane. The horses in group D showed significantly better 
recovery scores (longer time until first attempt to stand and fewer attempts to stand needed) 
than the control group. The observed cardiopulmonary effects produced by the α2-agonists in 
this study confirmed the results seen in Gozalo-Marcilla et al. (2010). 
Gozalo-Marcilla et al. (2013a) published an experimental study looking at how a dexmede-
tomidine CRI would affect the MAC of inhalation anaesthetic. The study included six ponies 
that were anaesthetised twice with a washout period of three weeks. Three ponies were, after 
induction, first administrated a 3.5 µg·kg-1 bolus dose of dexmedetomidine followed by a CRI 
of 1.75 µg·kg-1·hour-1 and the other time with a 3.5 µg·kg-1 bolus dose of saline followed by a 
CRI of 1.75 µg·kg-1·hour-1 of saline. The other ponies received the treatments in the opposite 
order. Anaesthesia was induced and maintained with sevoflurane and no premedication was 
administrated. During anaesthesia the ponies were electrically stimulated in order to evaluate 
if dexmedetomidine made it possible to reduce the concentration of inhalation anaesthetic. All 
six ponies showed a decreased MAC when given dexmedetomidine compared to saline. The 
decrease was significant with a reduction of sevoflurane by 53% (Gozalo-Marcilla et al., 
2013a). 
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Gozalo-Marcilla et al. (2013b) published yet another study (clinical, blinded and 
randomized), comparing the effects of a dexmedetomidine (group D) versus a morphine 
(group M) CRI in 20 isoflurane anaesthetised horses undergoing elective surgery (ASA I-II). 
The horses in group D were premedicated with a 3.5 µg·kg-1 bolus dose of dexmedetomidine 
followed by a CRI of 1.75 µg·kg-1·hour-1 during anaesthesia. The horses in group M were 
premedicated with a 3.5 µg·kg-1 bolus dose of dexmedetomidine and morphine (0.15 mg·kg-1) 
followed by a CRI of morphine (0.1 mg·kg-1·hour-1). The horses receiving only 
dexmedetomidine showed a significantly more stable anaesthetic depth (fewer alterations in 
the isoflurane concentration was needed), had a reduced MAC of isoflurane after 60 minutes 
of surgery and showed better recoveries. Group D also had a significantly higher MAP, 
significantly lower CI and SVI but the changes were within clinically acceptable levels 
(Gozalo-Marcilla et al., 2013b).  
Gozalo-Marcilla et al. (2014) compared horses receiving a CRI with only morphine (control 
group) versus horses receiving a CRI with both morphine and dexmedetomidine (group D) 
during anaesthesia. The study included five ponies and they were anaesthetised twice with a 
washout period of three weeks. One time they were administrated a 0.15 mg·kg-1 bolus dose 
of morphine followed by a CRI of 0.1 mg·kg-1·hour-1 during inhalation anaesthesia and the 
other time they were administrated a bolus dose of both morphine (0.15 mg·kg-1) and 
dexmede-tomidine (3.5 µg·kg-1) followed by a CRI of both morphine (0.1 mg·kg-1·hour-1) 
and dexmedetomidine (1.75 µg·kg-1·hour-1). This was an experimental study in which the 
horses were electrically stimulated during anaesthesia. The study showed that group D had a 
significant reduced MAC of sevoflurane (mean MAC 0.89%) compared to the control group 
(mean MAC 2.79%) with a mean reduction of 67% (Gozalo-Marcilla et al., 2014).  
Risberg et al. (2016) performed an experimental blinded study including eight anaesthetised 
horses. One group was administrated a 1.75 µg·kg-1·hour-1 CRI of dexmedetomidine (group 
D) and the control group received a saline CRI of the same volume. Both groups were 
premedicated with an 8 µg·kg-1 bolus of dexmedetomidine. The horses were subjected to 
electrical stimulus. At an equivalent depth of anaesthesia the horses in group D showed a 22% 
reduction in MAC of isoflurane compared to the control group. The horses receiving 
dexmedetomidine CRI showed a significantly decreased HR and CI, and increased arterial 
blood pressure. All horses in group D stood on the first attempt in recovery while the horses 
in the control group required a median of three attempts. This was the first study including the 
pharmacokinetics of a dexmedetomidine CRI during anaesthesia (Risberg et al., 2016). 
Sacks et al. (2017) included 60 horses undergoing elective surgery (ASA I-II) in a clinical, 
blinded study comparing the effects dexmedetomidine (a 3.5 µg·kg-1 bolus followed by a CRI 
of 1.75 µg·kg-1·hour-1) versus medetomidine (a 7 µg·kg-1 bolus followed by a CRI of 3.5 
µg·kg-1·hour-1) during anaesthesia maintained with isoflurane. Significantly more horses 
receiving dexmedetomidine needed supplemental doses of dexmedetomidine in order to fulfil 
the sedation criteria prior to induction. The cardiopulmonary effects or end-tidal isoflurane 
concentration (EtISO) did not differ significantly between the groups. The horses in the 
dexmedetomidine group showed a significantly better recovery compared to the horses 
receiving medetomidine (Sacks et al., 2017). 
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MATERIALS AND METHODS 
Study design 
This was a prospective, experimental study performed at the Swedish University of 
Agricultural Sciences under standardised conditions striving to mimic a clinical situation as 
far as possible. The study was conducted without a control group of horses. The six horses 
included in the study worked as their own control in the way that data was collected before 
the horses started receiving dexmedetomidine.  
Horses  
All horses included in the study were private owned and donated by their owners to be part of 
the present study. The horses were of different breed and size (Table 1). At the end of 
anaesthesia the horses were euthanized. The horses were fasted for 12 hours prior to 
anaesthesia. Water was not withheld.  
Table 1. Horses included in the study 
Horse  Breed Age Gender Weight (kg) 
1 Welsh pony 15 Gelding 275 
2 Swedish warmblood 18 Mare 615 
3 Swedish warmblood 18 Mare 676 
4 Swedish riding pony 20 Mare 450 
5 Quarter horse 18 Gelding 650 
6 Swedish warmblood 21 Gelding 750 
 
 
Instrumentation and anaesthesia 
The horses were premedicated with 0.03 mg·kg-1 acepromazine (Plegicil 10 mg·mL-1; 
Pharmaxim, Sweden) intramuscularly, 45 minutes before anaesthesia was induced. 
Before induction, the areas in which all catheters were placed were clipped and aseptically 
prepared. The skin was locally infiltrated with mepivacaine (Carbocain 2%; Aspen Nordic, 
Denmark). The venous catheter (Intranule, 14-gauge; Vygon, Sweden) was placed in the left 
jugular vein and only used for administration of drugs and Ringer Acetate infusion. Two 
catheter-introducers (One-piece Catheter Introducer, 8.5 Fr; ArgonMedical Devieces Inc; 
USA) were placed in the right jugular vein (one introducer 15 cm more proximally than the 
other) using the Seldinger technique.  
The anaesthesia was induced with guaifenesin (Myorelax 100 mg·mL-1; Dechra, UK) and 
thiopental (Thiopental Ebb; Ebb Medical, Sweden). Guaifenesin was given intravenously 
symptomatically (approximately 100-150 mL/100 kg bodyweight) until the horses started to 
show ataxia.  
Thiopental was resolved in sterile water and the solution (which was prepared in advance) 
was given intravenously (initially ½ gram/100 kg bodyweight, although some horses needed 
an extra bolus of 10% of the start dose).  
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The horses were intubated with a cuffed endotracheal tube and placed in dorsal recumbency. 
The tube was connected to a large animal circle breathing system (Tafonius T33; Vetronic 
Services Ltd, UK) and anaesthesia was maintained with isoflurane (Attane vet. 1000 mg/g; 
VM Pharma, Sweden) in oxygen. Intermittent positive pressure ventilation (IPPV) was 
applied. A tidal volume (TV) of 10 mL·kg-1, a respiratory rate (RR) of 7 breaths·minute-1 and 
a peak inspiratory pressure (PIP) of 25 cmH2O was set (PIP had to be adjusted in some of the 
horses).  
During anaesthesia, Ringer´s acetate solution (Ringer-Acetate; Fresenius Kabi, Sweden) was 
infused at a rate of approximately 5 mL·kg-1·hour-1. A urinary catheter was placed. 
After connection to the anaesthesia machine, a catheter (Criticath, 7 Fr, 110 cm; Argon 
Medical Devieces Inc, USA) was passed through the distal introducer in the right jugular vein 
and placed in the pulmonary artery. The catheter was correctly positioned by observing the 
blood pressure waveforms displayed on a cardiovascular monitor (Datex Ohmeda; GE 
healthcare). This catheter was used to measure CO and pulmonary artery pressure (PAP) as 
well as for collection of central venous blood for the venous blood gases. A Pigtail catheter 
was passed through the proximal introducer, placed in the right atrium and connected to the 
same pressure transducer as the arterial catheter. This catheter was used to measure central 
venous pressure (CVP).  
The arterial catheter (BD Venflon Pro, 20-gauge; BD, Switzerland) was placed in the facial 
artery and connected to a pressure transducer (Hemodynamic Monitoring System; BD, 
Switzerland) placed at the level of the right atrium and zeroed to atmospheric pressure. The 
arterial catheter was used for measurement of invasive arterial pressure and collection of 
blood samples (for analysis of blood gases and dexmedetomidine concentration).  
Dexmedetomidine (Cepedex 0.5 mg·mL-1; VM Pharma, Sweden) was diluted in 500 mL 
saline (Sodium chloride 0.9%; Fresenius Kabi, Sweden), and the horses received a 
dexmedetomidine CRI of 1.75 µg·kg-1·hour-1 using an infusion pump (Infusomat Space; 
Braun, Sweden). No bolus dose (or premedication) of dexmedetomidine was given.  
Thirty minutes after the dexmedetomidine CRI was started, a dobutamine infusion was 
initiated (Dobutamin Carino 250 mg/50 mL; Carinopharm, Germany) using a syringe pump 
(IVAV P3000; Alaris). The horses started the dobutamine CRI at a rate of 0.5 µg·kg-1·minute-
1 and the rate was then adjusted as required in order to keep MAP at 70-75 mmHg during the 
entire anaesthesia.  
During the anaesthesia the horses also received pulsed inhaled nitric oxide (PiNO) though a 
special built device (Datex-Ohmeda Research Unit, Finland) connected to the endotracheal 
tube. The nitric oxide was delivered as a pulse during the first part of every breath. The 
negative pressure that preceded the inhalation of gas stimulated the device. 
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Collection of data and analysis 
Table 2. Samples were collected and parameters recorded according to following schedule  
 Blood 
samples for 
dex conc. 
Arterial  
& venous blood 
gases 
HR, SAP/DAP, MAP,  
PAP, EtCO2, FiO2,  
EtO2, EtISO, PIP 
CVP, CO,  
PA wedge, 
temperature 
Start IPPV 
Start of isoflurane 
--- --- --- --- 
Baseline 60 ✓ ✓ ✓ ✓ 
Start dexmedetomidine --- --- --- --- 
Dex 15 
15 minutes after start of CRI 
✓ ✓ ✓ --- 
Dex 30 
30 minutes after start of CRI 
✓ ✓ ✓ ✓ 
Start dobutamine (dob) --- --- --- --- 
Dex 45 + dob 
15 minutes after start of dob. 
--- ✓ ✓ --- 
Dex 60 + dob 
30 minutes after start of dob.  
✓ ✓ ✓ ✓ 
Start PiNO --- --- --- --- 
Dex 75 + dob + PiNO  
15 minutes after start of PiNO 
--- ✓ ✓ --- 
Dex 90 + dob + PiNO  
30 minutes after start of PiNO 
✓ ✓ ✓ ✓ 
Stop PiNO --- --- --- --- 
Dex 105 + dob 
15 minutes after stopping PiNO 
--- ✓ ✓ --- 
Dex 120+ dob 
30 minutes after stopping PiNO 
✓ ✓ ✓ ✓ 
Stop dexmedetomidine --- --- --- --- 
Elimination 5 
5 minutes after stopping dex 
✓ --- ✓ --- 
Elimination 10 ✓ --- ✓ --- 
Elimination 15 ✓ ✓ ✓ ✓ 
Elimination 20 ✓ --- ✓ --- 
Elimination 30 ✓ ✓ ✓ ✓ 
Elimination 40 ✓ --- ✓ --- 
Elimination 50 ✓ --- ✓ --- 
Elimination 60 ✓ ✓ ✓ ✓ 
Stop anaesthesia 
Euthanisation 
--- --- --- --- 
✓ = measured/collected --- = not measured/collected 
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After induction the horses were maintained on isoflurane anaesthesia for 60 minutes in order 
for a steady state to be achieved before the dexmedetomidine CRI was initiated.  
Both the arterial and venous samples were collected in syringes with 0.1 mL added 
heparin/tube (Heparin LEO 5000 IE·mL-1; LEO Pharma, Denmark). The blood samples were 
collected over three breaths and the venous and arterial blood were collected at the exact same 
time. Blood gases were immediately analysed using an ABL 90 FLEX PLUS; Radiometer, 
Denmark. Before sampling, 3 mL blood was withdrawn and wasted.  
The blood samples used to analyse the dexmedetomidine concentration were collected from 
the fascial artery. Before sampling, 3 mL blood was withdrawn and wasted. The blood was 
transferred into heparinized tubes (BD Vacutainer Lithium Heparin; BD, Switzerland). The 
tubes were stored on ice and after the sampling kept on ice until centrifugation. The plasma 
was harvested and stored in a freezer until analysis (AdmeScope; Finland). Lowest 
concentration level of detection (LoD) was defined as 0.02 ng·mL-1. 
Cardiorespiratory parameters were recorded on the anaesthesia monitor and the 
cardiovascular monitor (Table 2). An ECG recorded HR and heart rhythm. Cardiac output 
was measured by bolus thermodilution. Iced saline (30 mL) was injected into the right atrium 
during the expiratory phase of the respiratory cycle. The change in blood temperature was 
measured in the pulmonary artery and CO calculated. Three injections were made at every 
measurement and the average value was used for the analysis. The saline had to be injected 
rather quickly and the quality of the waveform on the monitor confirmed the injection was 
fast enough.  
The anaesthetic depth was evaluated every five minutes (cardiovascular parameters and 
reflexes) and the inspired isoflurane concentration was adjusted according to the clinical 
parameters in order to keep the horse in sufficient anaesthetic depth. The total length of the 
anaesthesia was approximately four hour.  
Calculation of data 
Cardiac index (𝐶𝐼) = !"!"#$ !"#$!!    
Systemic vascular resistance index (𝑆𝑉𝑅𝐼) =  !"#!"  
 
Statistical analysis 
All collected data was compiled in Microsoft Excel 2011.  The statistical analysis was made 
with GraphPad Prism 7.0. The graphs were designed in Excel. The dots in the graphs indicate 
the time of sampling.  
A Wilcoxon matched-pairs signed rank test was used to calculate statistical significance. 
Regarding evaluation of heart rate during the elimination phase, a Friedman ANOVA with 
Dunn´s multiple comparison test was used. A confidence interval of 95% was applied and 
p<0.05 indicated statistical significance. 
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RESULTS 
Part 1) Dexmedetomidine plasma concentration 
Within the first measurement after the start of the CRI, the nociceptive threshold (0.15 ng·mL-
1) was reached with a marginal in all of the horses (Figure 1). In one horse, the plasma 
concentration was below the nociceptive threshold 30 minutes after the disconnection of the 
CRI, while four horses still were above the threshold 60 minutes after the disconnection 
(Table 3). 
Table 3. Concentration (ng/mL) of dexmedetomidine in arterial blood during anaesthesia. 
LoD<0.02 ng·mL-1 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6 
Start dex <LoD <LoD <LoD <LoD <LoD <LoD 
Dex 15 1.02 1.03 0.81 0.74 0.75 0.78 
Dex 30 1.20 1.34 1.13 1.02 0.89 1.01 
Dex 45 + dob 1.13 1.41 1.12 1.08 0.80 1.15 
Dex 60 + dob + PiNO 0.96 1.37 0.93 0.99 0.69 1.03 
Dex 120 +dob 0.79 1.25 1.03 0.92 0.68 0.91 
Elimination 5 0.30 0.82 1.04 0.54 0.35 0.53 
Elimination 10 0.42 0.65 0.60 0.45 0.27 0.43 
Elimination 15 0.35 0.50 0.51 0.34 0.22 0.37 
Elimination 20 0.30 0.44 0.44 0.33 0.18 0.32 
Elimination 30 0.14 0.29 0.36 0.28 0.15 0.26 
Elimination 40 0.12 0.21 0.27 0.25 0.13 0.21 
Elimination 50 0.11 0.18 0.24 0.21 0.11 0.19 
Elimination 60 0.10 0.16 0.18 0.18 0.10 0.18 
 
Figure 1. Mean ± SD of dexmedetomidine plasma concentration during and after the CRI in 
six horses.   
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Part 2) Circulation  
Heart rate was significantly decreased during a dexmedetomidine CRI of 1.75 µg·kg-1·hour-1. 
Heart rate increased rapidly after the disconnection of the dexmedetomidine CRI (Figure 2).  
Mean arterial blood pressure was significantly increased by the dexmedetomidine CRI 
(Figure 2). The dobutamine infusion rapidly and significantly increased MAP in all of the 
horses (Figure 3). The concentration of dobutamine was then adjusted during anaesthesia in 
order to keep MAP at 70-75 mmHg.  
Mean cardiac index was not significantly changed by the dexmedetomidine CRI. Cardiac 
index decreased in five of the six horses after the start of dexmedetomidine CRI; however 
horse 3 differed and instead CI increased (Figure 3). The dobutamine infusion rapidly and 
significantly increased CI in all of the horses.  
Relation between dexmedetomidine concentration and circulation 
 
Figure 2. Mean values of HR, MAP, CI (left axis) and dexmedetomidine concentration in 
arterial blood (right axis).  
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Figure 3. HR, MAP, CI (left axis) and dexmedetomidine concentration in ng·mL-1 (right axis).  
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Circulation during dexmedetomidine and dobutamine CRI 
Heart rate  
Heart rate decreased significantly during the dexmedetomidine CRI (Figure 4a) and was 
significantly lower at dex 15, dex 30, dex 45+dob and dex 60+dob (p<0.05) compared to 
baseline 60. After that heart rate was no longer significantly different compared to baseline 
60 (Table 4).  
MAP  
Mean arterial blood pressure increased significantly during the dexmedetomidine CRI and 
was significantly higher at dex 15 p<0.05 compared to baseline 60. At dex 30 MAP was still 
higher in five of six horses compared to baseline 60 but the average MAP for the group was 
not significantly different from baseline 60 (p=0.09).  
During the dobutamine infusion MAP increased significantly (Figure 4b) compared to both 
baseline 60 and dex 30; dex 45+dob and dex 60+dob (p<0.05) (Table 4).  
Cardiac index 
Cardiac index did not change significantly during the dexmedetomidine CRI (Figure 4c) 
compared to baseline 60 (p=0.2 at dex 30) (Table 4).  
During dobutamine infusion CI increased significantly (p<0.05 at dex 60+dob) compared to 
before dobutamine was given (dex 30). Horse 1 was not included since no cardiac index was 
obtained from this horse at dex 60+dob.  
Table 4. Mean ± SD of cardiovascular parameters during anaesthesia 
 HR 
 (beats·min-1) 
MAP 
(mmHg) 
CI 
(mL·kg-1·min-1) 
SVRI 
(mmHg·kg-1·min-1) 
Baseline 60 42 ± 5 
n = 6 
46 ± 7 
n = 6 
39 ± 11 
n = 6 
1.2 ± 0.4 
n= 6  
Dex 15 37 ± 4 ↓ 
n = 6 
55 ± 6 ↑ 
n = 6 
  
Dex 30 36 ± 3 ↓ 
n= 6 
54 ± 7 ↔ 
n = 6 
34 ± 3 ↔ 
n = 6 
1.6 ± 0.3 ↔ 
n= 6  
Dex 45 + dob 37 ± 5 ↓ 
n = 5 
79 ± 4 ↑ 
n = 5 
  
Dex 60 + dob 38 ± 6 ↓ 
n = 6 
76 ± 4 ↑ 
n = 5 
63 ± 11 ↑ 
n = 5 
1.2 ± 0.2 ↔ 
n = 6   
↓ = Significant decrease compared to baseline 60.  
↑ = Significant increase compared to baseline 60.  
↔ = No significant increase/decrease compared to baseline 60. 
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Figure 4a, 4b and 4c. Mean ± SD of HR, MAP and CI during the dexmedetomidine and 
dobutamine CRI, calculated in relative change with 100% at baseline 60. 
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Circulation during elimination phase of dexmedetomidine 
Heart rate  
The heart rate was significantly increased (Figure 5a) 30 to 60 minutes after the disconnection 
of the dexmedetomidine CRI (p<0.05 from elimination 30 to elimination 60) compared to the 
final recording before the dexmedetomidine CRI was disconnected (dex 120+dob) (Table 5).  
MAP  
No significant change in MAP occurred after the dexmedetomidine CRI was disconnected 
(Figure 5b and Table 5). 
Cardiac index  
No significant change in CI occurred after the dexmedetomidine CRI was disconnected 
(Figure 5c and Table 5). 
Table 5. Mean ± SD of cardiovascular parameters during the elimination phase 
 HR 
 (beats·min-1) 
MAP 
(mmHg) 
CI 
(mL·kg-1·min-1) 
SVRI 
(mmHg·kg-1·min-1) 
Dex 120 + dob 44 ± 8 
n = 6  
73 ± 9 
n = 6 
83 ± 10  
n = 6 
0.8 ± 0.1 
n = 6  
Elimination 5 51 ± 11 ↔ 
n = 6 
69 ± 9 ↓ 
n = 5 
  
Elimination 10 55 ± 10 ↔ 
n = 6 
67 ± 7 ↓ 
n = 5 
  
Elimination 15 60 ± 11 ↔ 
n = 6 
69 ± 10 ↔ 
n = 6 
91 ± 9 ↔ 
n = 3 
0.7 ± 0.1 ↔ 
n = 3 
Elimination 20 61 ± 12 ↔ 
n = 6 
69 ± 9 ↔  
n = 5 
  
Elimination 30 64 ± 11 ↑ 
n = 6 
67 ± 4 ↔ 
n = 6 
108 ± 21 ↔ 
n = 4 
0.6 ± 0.1 ↔ 
n = 4 
Elimination 40 68 ± 10 ↑ 
n = 6  
68 ± 6 ↔ 
n = 6 
  
Elimination 50 62 ± 11 ↑ 
n = 6 
67 ± 12 ↔ 
n = 5 
  
Elimination 60 60 ± 13 ↑ 
n = 6  
69 ± 8 ↔ 
n = 6 
90 ± 13 ↔  
n = 6 
0.8 ± 0.1 ↔ 
n = 6  
↓ = Significant decrease compared to dex 120+dob.  
↑ = Significant increase compared to dex 120+dob.   
↔ = No significant increase/decrease compared to dex 120+dob. 
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Figure 5a, 5b and 5c. Mean ± SD of HR, MAP and CI after the dexmedetomidine CRI was 
disconnected, calculated in relative change with 100% at dex 120+dob. 
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Part 3) Isoflurane concentration 
A dexmedetomidine CRI of 1.75 µg·kg-1·hour-1 did not significantly decrease end-tidal 
isoflurane concentration (compared to baseline 60) during the anaesthesia. 
The horses showed an individual difference regarding the amount of isoflurane they needed in 
order to stay at an equivalent and ideal depth of anaesthesia (Figure 6b). A decrease in mean 
end-tidal isoflurane concentration over time was seen (Figure 6a) although the change was not 
significant. 
 
Figure 6a. Mean ± SD values of end-tidal concentration of isoflurane during anaesthesia, 
calculated in relative change with a 100% at baseline 60. 
 
Figure 6b. Individual end-tidal isoflurane concentration during anaesthesia.   
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Part 4) Arterial oxygenation 
Horse 1 received PiNO for 30 minutes before dobutamine was administrated during the 
dexmedetomidine CRI. The following horses received PiNO for 30 minutes during the 
combined dexmedetomidine and dobutamine CRI.  
The reason for the change in order was to optimise blood flow and increase the blood pressure 
before PiNO was administrated in order for the nitric oxide to have full effect.  
Table 6. Mean ± SD of oxygenation parameters during anaesthesia 
 PaO2 
(kPa) 
SaO2 
(%) 
PAPM  
(mmHg) 
Baseline 60 8.6 ± 3.1 
n = 6 
88 ± 8 
n = 6 
16 ± 4 
n = 6 
Dex 30 6.3 ± 1.2 ↓ 
n = 6 
80 ± 9 ↓ 
n = 6 
16 ± 3 ↔ 
n = 6 
Dex 60 + dob 8.0 ± 1.7 ↔ 
n = 5 
85 ± 7 ↔  
n = 5 
19 ± 4 ↑ 
n = 5 
Dex 75 + dob + PiNO 15.4 ± 7.2 ↑ 
n = 6 
94 ± 2 ↑ 
n = 6 
19 ± 4 ↔ 
n = 6 
Dex 90 + dob + PiNO 20.0 ± 8.2 ↑ 
n = 6 
96 ± 1 ↑ 
n = 6 
19 ± 7 ↔ 
n = 6 
Dex 120 + dob 14.5 ± 6.3 ↑ 
n = 6 
94 ± 2 ↑ 
n = 6 
24 ± 5 ↑ 
n = 6 
Elimination 60 13.6 ± 6.3 ↔ 
n = 6 
94 ± 2 ↔ 
n = 6 
21 ± 6 ↔ 
n = 6 
↓ = Significant decrease compared to baseline 60.  
↑ = Significant increase compared to baseline 60.  
↔ = No significant increase/decrease compared to baseline 60. 
 
Partial pressure of arterial oxygen and oxygen saturation in arterial blood slowly decreased 
after the horses were anaesthetised (Figure 7a and 8a). There was no change in the arterial 
oxygen parameters during the dobutamine infusion.  
A pronounced increase in PaO2 and SaO2 was measured when PiNO was administrated in all 
six horses (Figure 7b and 8b). Even though PiNO was only administrated for 30 minutes 
during the anaesthesia the partial pressure and oxygen saturation in arterial blood remained 
high during the entire anaesthesia (Table 6).  
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Arterial oxygen saturation 
There was a significant decrease in oxygen saturation (SaO2) in arterial blood during the 
dexmedetomidine CRI (p< 0.05 at dex 30 compared to baseline 60). At dex 60+dob there was 
no significant change. The oxygen saturation increased significantly during PiNO (p<0.05 at 
dex 75+dob+PiNO, dex 90+dob+PiNO and dex 120+dob compared to baseline 60).  
Also, oxygen saturation increased significantly during PiNO compared to the measurement 
before PiNO was commenced (p<0.05 at dex 75+dob+PiNO and dex 90+dob+PiNO 
compared to dex 60+dob).  
 
Figure 7a. Mean ± SD of oxygen saturation in arterial blood during anaesthesia. 
 
Figure 7b. Individual oxygen saturation in arterial blood during anaesthesia. 
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Partial pressure of arterial oxygen  
There was a significant decrease in partial pressure of arterial oxygen (PaO2) during the 
dexmedetomidine CRI (p< 0.05 at dex 30 compared to baseline 60). At dex 60+dob there was 
no significant change. The partial pressure increased significantly during PiNO (p<0.05 at dex 
75+dob+PiNO, dex 90+dob+PiNO and dex 120+dob compared to baseline 60).  
Also, PaO2 increased significantly during PiNO compared to the measurement before PiNO 
was commenced (p<0.05 at dex 75+dob+PiNO and dex 90+dob+PiNO compared to dex 
60+dob).  
 
Figure 8a. Mean ± SD of partial pressure of oxygen in arterial blood during anaesthesia, 
calculated in relative change with a 100% at baseline 60. 
 
Figure 8b. Individual partial pressure of oxygen in arterial blood during anaesthesia. 
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DISCUSSION 
The major findings in the present study were that an intravenous infusion of 1.75 µg·kg-1·hour-1 dexmedetomidine during inhalation anaesthesia resulted in plasma concentration 
above the previously described threshold of 0.15 ng·mL-1 determined in conscious horses. 
Including dexmedetomidine CRI during inhalation anaesthesia resulted in decreased heart 
rate, cardiac index and arterial oxygenation while arterial blood pressure increased. Adding a 
dobutamine CRI during the dexmedetomidine CRI improved cardiac index and mean arterial 
blood pressure. The end-tidal isoflurane concentration could not be reduced during the 
dexmedetomidine CRI however no surgery was performed in this experimental study. Finally, 
introducing PiNO during on-going dexmedetomidine and dobutamine CRI improved arterial 
oxygenation and oxygen delivery.  
No reported previous study has analysed pharmacodynamic effects of a dexmedetomidine 
CRI after disconnecting the CRI during ongoing inhalation anaesthesia. In the present study 
physiological parameters and dexmedetomidine concentration in plasma were analysed during 
60 minutes after the disconnection of the dexmedetomidine CRI.  
The major limitation of the study was that a blinded study with a control group of horses 
would have been preferable but that was not feasible with the limited number of horses 
available in the present study.  
Another limitation in the present study was the non-objective method of evaluating the 
anaesthetic depth in the horses. Looking at ocular parameters is a rather rough method of 
assessing anaesthetic depth and small differences in isoflurane requirements may easily go 
undetected. Introduction of a flow-chart in order to more correctly asses the anaesthetic depth 
probably needs to be introduced if dexmedetomidine was to be included in the anaesthesia 
protocol.  
Dexmedetomidine plasma concentration 
The dose 1.75 µg·kg-1·hour-1 has been used in several studies and one reason to choose this 
dose was to be able to compare the results in the present study with the results reported in 
previous studies (Gozalo-Marcilla et al., 2010; Gozalo-Marcilla et al., 2012; Gozalo-Marcilla 
et al., 20123a; Gozalo-Marcilla et al., 2013b; Gozalo-Marcilla et al., 2014; Risberg et al., 
2016; Sacks et al., 2017). 
In the present study we assumed the nociceptive threshold to be 0.15 ng·mL-1, a concentration 
Risberg et al., (2014) reported to fulfill all of the nociceptive parameters analysed in their 
study, although some nociceptive qualities were evident even at plasma concentrations <0.02 
ng·mL-1 (the lowest detectable limit of dexmedetomidine in plasma). Their study was not 
blinded, which would have been preferable. Also, their study was performed on conscious 
horses, and the nociceptive threshold could differ between conscious and anaesthetised 
horses. However, there is no equivalent study on nociception during dexmedetomidine CRI 
on anaesthetised horses yet. 
  
 
24 
A significant individual difference in plasma concentration after administration of 
dexmedetomidine (both after a CRI and after a single bolus dose) has been reported in 
conscious horses (Risberg et al., 2014; Ranheim et al., 2015). During general anaesthesia, 
dexmedetomidine plasma concentrations are much less variable between the individual horses 
(Risberg et al., 2016; Hopster et al., 2014). In the present study, the individual variation of the 
dexmedetomidine plasma concentration was relatively small.  
In the present study, the plasma dexmedetomidine concentration seen in all horses 30 minutes 
after the start of the 1.75 µg·kg-1·hour-1 dexmedetomidine CRI, was higher than the 
concentration in standing horses receiving a 8 µg·kg-1·hour-1 dexmedetomidine CRI 30 
minutes after the start of the CRI (Ranheim et al., 2015). The difference is striking, 
demonstrating possible differences in distribution and elimination in conscious versus 
anaesthetised horses. In standing horses administered a dexmedetomidine CRI at a rate of 2 
µg·kg-1·hour-1 (Risberg et al., 2014), the mean plasma concentration of dexmedetomidine 
was ten times lower than in anaesthetised horses receiving 1.75 µg·kg-1·hour-1. This indicates 
that the pharmacokinetic profile differs in awake and anaesthetised horses, most likely due to 
reduced CO caused by co-administration of other anaesthetics and sedatives, probably 
interfering with the dexmedetomidine elimination (Ranheim et al., 2015).  
It has been discussed in other studies (Gozalo-Marcilla et al., 2010) that a loading dose of 
dexmedetomidine should be included in the protocol before the CRI is started in order to 
rapidly achieve an adequate plasma concentration, however in the present study we could 
show that no bolus dose was required under anaesthesia circumstances. Dexmedetomidine 
quickly reached a significant plasma concentration after the start of the chosen CRI, despite a 
relatively slow distribution of dexmedetomidine. The concentration rapidly reached the 
nociceptive threshold (with a mean concentration of 0.85 ng/mL 15 minutes after the start of 
the CRI). In two horses the plasma concentration was <0.15 ng·mL-1 30-40 minutes after 
disconnection of the CRI, but the remaining four horses had concentration >0.15 ng·mL-1 still 
after 60 minutes. 
Circulation 
It cannot be ruled out that other drugs used during premedication, induction and anaesthesia 
may have influenced the physiological effects seen in the present study. Acepromazine 
decreases the vascular tone, produces hypotension but might enhance blood flow. 
Acepromazine is used routinely as a premedication before equine anaesthesia and has shown 
to reduce the mortality rate in horses when being used as premedication before anaesthesia 
(Doherty et al., 2006). Dobutamine is regularly administrated during anaesthesia in order to 
control blood pressure. Most likely did this influence our results as dobutamine improves 
cardiac performance (Kalchofner et al., 2009). Since thiopental is reported to cause an 
increased heart rate, decreased contractility and vasodilatation, thus leading to hypotension 
and decreased pre-load, its administration could also have affected the results. Guaifenesin 
has minimal cardiovascular effects and should probably not influence the results in the 
present study. Neither acepromazine, thiopental, guaifenesin nor isoflurane provide any 
analgesic properties (Doherty et al., 2006). 
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In many of the previous studies, our study included, the cardiovascular changes seen with 
dexmedetomidine were short-lived and mainly occurred in the initial phase at the start of the 
dexmedetomidine CRI, even though dexmedetomidine potentially had not reached steady 
state in plasma concentration at that time point.  
One study (Gozalo-Marcilla et al., 2010), showed no significant difference between 
administra-tions of a 1 µg·kg-1·hour-1 CRI versus 1.75 µg·kg-1·hour-1, indicating that there 
probably is a ceiling effect regarding the side effects of dexmedetomidine. The analgesic and 
sedative effects caused by dexmedetomidine have an upper limit, meaning that increasing the 
dose will not provide more sedation or analgesia, only extend the duration of the effects (and 
side effects). The results from this study indicates that the expected cardiovascular changes 
occur even at a low dexmedetomidine concentration and it is possible that increasing the CRI 
will not worsen the cardiovascular changes (Gozalo-Marcilla et al., 2010).  
The cardiovascular changes seen in the present study were consistent with results seen in 
previous studies. (Bettschart-Wolfensberger et al., 2005; Rezende et al., 2015). The 
cardiovascular changes remained within clinically acceptable levels but one has to bear in 
mind that cardiac index and arterial blood pressure was supported with dobutamine infusion 
and fluid therapy.  
Heart rate 
In the present study, the heart rate decreased in all six horses after the start of 
dexmedetomidine CRI with a mean reduction of 12% and 15% at 15 and 30 minutes 
respectively after the start of the dexmedetomidine CRI. The result was expected and 
consisting with the results from similar studies (Gozalo-Marcilla et al., 2010; Gozalo-Marcilla 
et al., 2012; Gozalo-Marcilla et al., 2013a; Gozalo-Marcilla et al., 2014; Risberg et al., 2016; 
Hopster et al., 2014). The decrease in heart rate was significantly lower during the first 60 
minutes after the start of the dexmedetomidine CRI, compared to baseline. Dexmedetomidine 
has been reported to induce bradycardia both by central mechanisms and as a reflex secondary 
to the initial vasoconstriction caused by the activation of α2B-adrenoceptors (Maze & 
Tranquilli, 1991). 
An interesting and surprising finding in the present study was the rapid increase in heart rate 
during the elimination phase of dexmedetomidine. Heart rate increased dramatically in all 
horses after the disconnection of the dexmedetomidine CRI and reached the highest value 40 
minutes after disconnection of the CRI. This finding is not described in the literature before, 
probably because no previous study as analysed physiological parameters after disconnection 
of the dexmedetomidine CRI during ongoing anaesthesia. The increased heart rate could be 
due to a compensatory mechanism induced by vasodilatation, once the vasoconstrictor effect 
of dexmedetomidine wears of. Another possibility could be a release of the inhibition of the 
sympathetic nervous system caused by a rapid clearance of the already low plasma 
dexmedetomidine level resulting in a rapid norepinephrine release (Gozalo-Marcilla et al., 
2010). 
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Arterial blood pressure (MAP) 
Arterial blood pressure increased immediately after the start of the dexmedetomidine CRI. 
The increase was, undoubtedly, caused by vasoconstriction. A vasoconstriction on endothelial 
smooth muscle leads to an increase in SVR and hence an increased arterial blood pressure 
(Maze & Tranquilli, 1991). In line with previous studies, the increase was short-lived; in the 
present study the increase was only significant during the first 15 minutes after the start of the 
CRI.  
A dexmedetomidine CRI during isoflurane anaesthesia may be used to improve the arterial 
blood pressure by vasoconstriction. However, since isoflurane has the opposite effect on the 
peripheral vascular tone, by inducing vasodilatation, dose dependent impairment in blood 
pressure and hypotension are common complications during equine anaesthesia (Lee, 2006). 
As expected, MAP increased rapidly when the horses received dobutamine and after that 
point it is difficult to analyse what effect dexmedetomidine may or may not have had on 
MAP. Nevertheless, studies have showed that horses receiving a medetomidine CRI need 
significantly less dobutamine during anaesthesia in order to support MAP (Kempshen et al., 
2012).  
Interestingly, no change in MAP was measured during the elimination phase, although the 
heart rate significantly increased. Even though no significant change was found MAP could 
be regulated by a slight decrease in stroke volume or SVR, or in both at the same time.  
Cardiac index 
In line with most previous studies, a significant reduction in cardiac index when 
administrating dexmedetomidine was expected. However, no significant change in cardiac 
index was seen in the present study, which is in line with the findings by Gozalo-Marcilla et 
al. (2012). The result could have been caused by a deviating value from one of the horses. All 
horses but one showed a decrease in cardiac index after the dexmedetomidine CRI was started 
but cardiac index increased in one horse in this study. 
The decrease in CI described in the literature is probably a result of the low HR. The reduced 
CI is most likely the reason to the impaired oxygen delivery described during the 
dexmedetomidine CRI. However, the decreased CI will probably not cause any issues in a 
clinical situation because the blood pressure can be preserved with infusion of dobutamine. 
In several of the previous studies the difference in CI between horses receiving 
dexmedetomidine and horses compared to a control groups was not significant. At the time 
when those studies were performed, the pharmacokinetics of dexmedetomidine in horses was 
not known. The pharmacokinetic results from the study by Risberg et al. 2016 indicate that 
the comparison of CI with a control group in numerous of the studies (Gozalo-Marcilla et al., 
2010, 2012; Gozalo-Marcilla et al., 2013a) probably was influenced by the premedication 
since the control groups also received dexmedetomidine as premedication.  
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Isoflurane concentration 
As seen in previous studies there was a considerable individual difference in isoflurane 
concentration between the horses. In the present study no significant change in end-tidal 
isoflurane concentration (EtISO) during or after the 1.75 µg·kg-1·hour-1 dexmedetomidine 
CRI could be shown. It is possible that no reduction was seen because the horses were not 
subjected to any stimuli.  
It is fair to assume that one reason to why dexmedetomidine (and other potent α2-agonists) 
have been shown to decrease the concentration of required inhalation anaesthetics is due to its 
analgesic properties. Isoflurane and other inhalation anaesthetics have none (or very poor) 
analgesic effects. During surgeries, it is therefore, normally, not possible to reduce the 
anaesthetic depth without administrating analgesics (Gozalo-Marcilla, 2013c). It is possible 
that a reduction of isoflurane concentration in the present study would have been possible if 
the included horses were subjected to painful stimuli, or rather more likely, we would have 
seen an increased need for higher isoflurane concentration in a control group of horses. 
The results regarding the concentration of inhalation anaesthetics during a dexmedetomidine 
CRI and whether it is possible or not to lower the concentration under the influence of 
dexmedetomidine are contradictive. One experimental study showed lower isoflurane 
concentration needed during anaesthesia with a dexmedetomidine CRI compared to a control 
group (Risberg et al., 2016). Gozalo-Marcilla et al. (2013b) could not show an overall 
difference in EtISO in horses receiving morphine versus dexmedetomidine during the first 60 
minutes of surgery, although the horses receiving dexmedetomidine gradually required lower 
concentration of isoflurane and the difference became significant after 60 minutes. The horses 
receiving dexmedetomidine in that study also spent a longer time in the ”ideal” depth of 
anaesthesia with fewer alterations in the isoflurane concentration compared to the horses 
receiving morphine.  
In the study from 2012 by Gozalo-Marcilla et al., where dexmedetomidine CRI failed to 
reduce the dose of isoflurane, one could argue that it could be because it was difficult to 
correctly assess the anaesthetic depth. One study showed that horses anaesthetised with a 
medetomidine CRI appeared more lightly in the anaesthetic depth (spontaneous blinking, 
tearing and other ocular parameters are often seen) even though they are in an ”ideal surgical 
anaesthetic depth” (HR and blood pressure are stable and no movements occur) (Kalchofner 
et al., 2006). Therefore, horses receiving a dexmedetomidine CRI may falsely be assessed as 
being in a light anaesthetic depth by the anaesthetist (Gozalo-Marcilla et al., 2012). Gozalo-
Marcilla et al. (2013b) used a flow-chart in their study in order to more correctly assess the 
anaesthetic depth. It has been suggested that arterial blood pressure and other physiological 
parameters could be more widely used, in addition to ocular parameters, to prevent horses 
receiving α2-agonists to be too deeply anaesthetised during surgery. It is also worth 
mentioning that in both of the above described clinical studies (Gozalo-Marcilla et al., 2012; 
Gozalo-Marcilla et al., 2013b), the horses in the control group also received 
dexmedetomidine as premedication, which could have affected the results. 
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Arterial oxygenation 
The positive effect of PiNO on the arterial oxygenation is well described in previous studies, 
both under experimental and clinical circumstances (Grubb et al., 2008; Grubb et al., 2012b; 
Nyman et al., 2012; Grubb et al., 2013; Wiklund, 2014). In the present study the aim was to 
analyse whether PiNO would work well together with a dexmedetomidine CRI. 
Both isoflurane and dexmedetomidine have an inhibitory effect on cardiac index. Also 
intermittent positive pressure ventilation (IPPV) results in a decreased cardiac index 
compared to spontaneously breathing horses. This because IPPV produces high intrathoracic 
pressure, which leads to a decreased venous blood return to the heart (Kalchofner et al., 
2009), by compression of the vena cava (Auckburally & Nyman, 2017). Impaired cardiac 
index can lead to secondary hypoxemia since a smaller amount of the blood flow will be 
oxygenated (Grubb, 2012a).  
As expected, the arterial oxygenation (both partial pressure of arterial oxygen and arterial 
oxygen saturation) was low initially during anaesthesia, probably due to the factors described 
above. Gozalo-Marcilla et al. (2012) showed that horses receiving a dexmedetomidine CRI 
during general anaesthesia had significantly lower PaO2 compared to the horses receiving a 
saline CRI. All of the six horses in the present study developed hypoxemia (PaO2 < 8.0 kPa) 
30 minutes after the dexmedetomidine CRI was started (two of the horses showed hypoxemia 
already at baseline). As seen in previous studies (Grubb et al., 2008; Grubb et al., 2012b; 
Nyman et al., 2012; Grubb et al., 2013; Wiklund, 2014) PiNO had a remarkable effect on 
PaO2 and SaO2. In the present study, PaO2 increased more than 200% and SaO2 was well 
above 90% during the treatment.  
Another finding was that horse 1 did not show the same degree of improvement after 
administration of PiNO as the other horses did (when receiving PiNO horse 1 increased PaO2 
with 60 % compared to baseline, in comparison with the rest of the horses that showed a mean 
increase of 140 %). This is most likely due to the fact that horse 1 did not receive dobutamine 
prior to PiNO, and therefore it is possible that cardiac index was too low to improve the 
perfusion distribution of well aerated lung regions. Thirty minutes later when also dobutamine 
was added, a more distinct increase in PaO2 was seen in this horse.  
In line with previous studies the effects of PiNO continued for approximately 30 minutes after 
termination of PiNO.  
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CONCLUSIONS 
In conclusion, the present study showed that a 1.75 µg·kg-1·hour-1 dexmedetomidine CRI 
during inhalation anaesthesia resulted in a plasma concentration well over the previously 
described nociceptive threshold (0.15 ng·mL-1). The significant cardiovascular effects caused 
by the dexmedetomidine CRI included a decrease in heart rate and an increase in mean 
arterial blood pressure. These effects were short-lived and within clinically acceptable levels.  
It was not possible to reduce the isoflurane concentration in the current experimental study 
possibly because it was carried out without painful stimuli. Most likely is the expected 
analgesic effect of dexmedetomidine CRI difficult to assess without any surgical stimuli.  
The study also shows that it was possible to treat both hypotension and hypoxemia with 
dobutamine and PiNO, respectively.  
Future studies are encouraged to evaluate the effect of dexmedetomidine during equine 
surgery and the following recovery period.  
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POPULÄRVETENSKAPLIG BESKRIVNING 
Detta var en experimentell studie som utfördes på universitetsdjursjukhusets hästklinik i 
Uppsala. Studien inkluderade sex hästar av varierande ras, ålder och kön. Hästarna sövdes på 
kliniken och vidhölls i narkos med narkosgasen isofluran. Målet med studien var att utvärdera 
hur hästarna påverkades av att lägga till dexmedetomidin, en substans med både lugnande och 
smärtstillande egenskaper, under narkosen.  
Narkos på häst är ett riskfyllt moment. Hästar drabbas lätt av blodtrycksfall och dålig 
syresättning när de är under narkos, mycket beroende på att de är placerade antingen på sidan 
eller på rygg vilket skapar ett högt tryck på lungorna. Den vanligaste metoden är att hästar 
sövs med narkosgas som dock oftast ger negativa effekter på cirkulation och andning. Det är 
därför eftersträvansvärt att hålla koncentrationen av inandad narkosgas så låg som möjligt 
men utan att riskera att hästen hamnar för ytligt i narkosen. För att undvika detta utförs flera 
studier för att hitta alternativ för att göra narkosen mer säker och minska risken för 
komplikationer.  
Den grupp av sederande (lugnande) läkemedel som används inom veterinärmedicinen är 
huvudsakligen så kallade alfa2-agonister, vilka också har smärtstillande egenskaper. Till den 
gruppen räknas även dexmedetomidin. Det är den mest potenta alfa2-agonisten och har i 
tidigare studier visat sig vara den alfa2-agonist som finns kvar kortast tid i kroppen efter en 
injektion. Det är en eftertraktansvärd egenskap, dels genom att det i teorin snabbt går att ändra 
graden av sedering genom att justera dosen, dels blir biverkningsprofilen mindre uttalad. 
Dexmedetomidin har visat sig ge samma biverkningar som andra alfa2-agonister men 
effekterna blir mer kortlivade.  
Läkemedlet kan dels ges som engångsdos intravenöst (i blodet) eller som ett kontinuerligt 
dropp/infusion (ett så kallat CRI) intravenöst. Dexmedetomidin har under en längre tid 
använts till hund och katt men substansen är relativt ny inom hästmedicinen. Den första 
studien där dexmedetomidin gavs till hästar genom ett CRI var 2005 och sedan dess har ett 
antal studier gjorts inom området, både där dexmedetomidin getts som ett komplement under 
narkos och vid stående ingrepp på vakna hästar. Dessa studier har visat att genom att 
administrera dexmedetomidin under narkos kan koncentrationen narkosgas sänkas, troligtvis 
genom dexmedetomidins smärtstillande egenskaper.  
Målet med denna studie var att studera huruvida koncentrationen isofluran kunde minskas 
under narkosen och hur dexmedetomidin påverkade hästarnas cirkulation. Ytterligare ett mål 
var att studera hur koncentrationen dexmedetomidin i blodet tedde sig samt hur syresättningen 
påverkades då hästarna samtidigt erhöll dexmedetomidin och pulsat inhalerat kvävemonoxid 
(PiNO).  
Hästarna sövdes och kopplades upp på narkosgas i operationsrummet. I en timme låg de 
enbart på narkosgas för att stabilisera sig och uppnå ett så kallat baseline. Efter 60 minuter 
startades ett CRI med dexmedetomidin med en koncentration på 1.75 µg·kg-1·h-1 (en 
koncentration som använts i flera tidigare studier).  
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Efter 30 minuter adderades en infusion med ett blodtryckshöjande läkemedel (dobutamin), 
vilket är en substans som används rutinmässigt under kliniska omständigheter för att hålla 
hästens blodtryck på en bra nivå under narkos. Ytterligare 30 minuter in i narkosen fick 
hästarna kväveoxid under en halvtimme, en substans som stimulerar respirationen och 
förbättrar syresättningen. När kväveoxiden stängdes av, låg hästarna kvar på infusion med 
dexmedetomidin och dobutamin i ytterligare en halvtimme innan infusionen med 
dexmedetomidin stängdes av. En timme senare avlivades hästarna på operationsbordet.  
Under hela experimentet togs blodprover efter ett förbestämt schema, dels för att analysera 
blodgaser och dels för att kunna analysera koncentrationen dexmedetomidin i blodet. 
Kontinuerligt utlästes och analyserades även olika cirkulatoriska och respiratoriska parametrar 
(bland annat hjärtfrekvens, artärblodtryck och hjärtminutvolym) samt koncentration isofluran. 
Resultaten sammanställdes och statistiska analyser genomfördes. De sex hästarna inkluderade 
i vår studie utgör enbart ett stickprov av den sanna hästpopulationen. I denna studie har 
statistisk signifikans räknats vid p<0.05 – det vill säga att sannolikheten att ett resultat (av 
signifikant värde) i vår studie med 95 % sannolikhet kommer överensstämma med övriga 
hästpopula-tionen. 
Isoflurankoncentrationen var inte signifikant lägre efter att hästarna gavs dexmedetomidin 
jämfört med baseline (innan infusionen med dexmedetomidin startades). Däremot minskade 
medelvärdet av isoflurankoncentration men skillnaden var inte tillräckligt stor för att vara 
signifikant.  
Hjärtfrekvensen minskade och denna förändring var signifikant den första timmen efter att 
dexmedetomidin började ges. Medelblodtrycket ökade signifikant de första 15 minuterna efter 
att dexmedetomidin börjades ges. Ingen signifikant skillnad kunde ses i hjärtminutvolym. 
Minskad hjärtfrekvens och ökat blodtryck är kända cirkulatoriska effekter som ses vid 
administrering av en alfa2-agonist. Förändringarna var dock kortlivade (liknande som setts i 
andra studier) och de cirkulatoriska värdena höll sig hela tiden inom en kliniskt acceptabel 
nivå.  
I andra studier har hästarna innan infusionen med dexmedetomidin erhållit en startdos 
dexmedetomidin, antingen som lugnande substans innan kastningen eller precis innan 
infusionen med dexmedetomidin startats under narkosen (en stötdos för att snabbt nå en hög 
koncentration i blodet). Denna studie var den första studien där hästarna inte erhållit 
dexmedetomidin innan infusionen påbörjades. Detta för att vi ville utvärdera huruvida en 
stötdos verkligen var nödvändig för att nå över den så kallade nociceptiva tröskeln (den 
koncentration dexmedetomidin i blodet som krävs för full smärtlindring vid smärtsamma 
stimuli) och dels för att vi inte ville att en tidigare given stötdos av dexmedetomidin skulle 
påverka resultaten. Vi kunde i vår studie visa att en loading dose inte krävs, trots den låga 
koncentrationen dexmedetomidin i infusionen i denna studie steg koncentrationen i blodet 
snabbt. Efter att infusionen med dexmedetomidin stängdes av sjönk koncentrationen på ett 
förväntat sätt. Sextio minuter efter avslutandet av infusionen låg koncentrationen 
dexmedetomidin i blodet i medeltal på 0,15 ng/mL (den koncentration som i en tidigare studie 
visat sig motsvara den nociceptiva tröskeln).  
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Slutsatsen var att de cirkulatoriska förändringarna orsakade av dexmedetomidin under 
narkosen var milda och kortvariga. Tyvärr sågs ingen reducering i isoflurankoncentrationen 
under de rådande omständigheterna men det kan förklaras genom att hästarna inte utsattes för 
något stimuli (som de gör under operationer). I denna experimentella studie kom inte 
dexmede-tomidins smärtstillande egenskaper till uttryck. Vi kunde också se att de vanligaste 
narkos-komplikationerna (blodtrycksfall och försämrad syresättning) framgångsrikt kunde 
behandlas med dobutamin och PiNO.  
Mer forskning krävs för att utvärdera hur dexmedetomidin skulle fungera under kliniska 
omständigheter.  
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